British Thoracic Oncology Group (BTOG) Annual Report - April 2014 to March 2015

Transcription

1 British Thoracic Oncology Group (BTOG) Annual Report - April 2014 to March 2015 BTOG s Aim BTOG is the multi-disciplinary group for professionals involved with thoracic malignancies. BTOG aims to improve the care of patients with thoracic malignancies through multidisciplinary education, developing and advising on guidelines for patient care and facilitating and nurturing clinical trial ideas into full protocols. The organisation now has a membership/e-circulation list of over 2,000 thoracic oncology health care professionals. BTOG members are from all professions involved in the care of lung cancer and mesothelioma throughout the UK and Ireland including medical and clinical oncologists, surgeons, radiotherapists, radiologists, nurses (specialist, research/trials, chemotherapy and academic), pharmacists and scientists. BTOG are a not for profit organisation which is kindly hosted by University Hospitals of Leicester NHS Trust (UHL) and the secretariat is based at Glenfield Hospital in Leicester. BTOG does not receive any funding from UHL or the NHS and at present receives financial support through sponsorship and educational grants from industry. BTOG Chair Professor Ken O Byrne formerly from St James s Hospital, Dublin and now Professor of Medical Oncology, Faculty of Health at Princess Alexander Hospital and Queensland University of Technology, Brisbane, Australia is the founding chair and president of BTOG. Dr Sanjay Popat (left), Consultant Medical Oncologist from the Royal Marsden Hospital, London took over the chair role in January 2013 (following BTOG 2013). Page 1 of 6

2 Education Programme of Events 13 th Annual BTOG Conference 2015 BTOG th to 30 th January 2015, Dublin BTOG 2015 attracted renowned speakers and chairs from the UK, Ireland, Europe, Australia, USA and Canada. The conference updated attendees on state of the art management of lung cancer and mesothelioma, increased understanding on the nature of clinical practice and research and facilitated networking for the development of new national and international clinical research studies in lung cancer and mesothelioma. Each year the British Thoracic Oncology Group (BTOG) gives a lifetime achievement award to an individual who in the steering committee s opinion has made a significant contribution to the management of thoracic malignancies in the UK and Ireland and this year this was presented to Dr Fergus Macbeth. BTOG 2015 was awarded 13 CPD Credits by the Royal Colleges of Physicians of the United Kingdom and 13 ESMO-MORA points category 1 by European Society for Medical Oncology (3 Wednesday and 6 Thursday and 4 Friday). The Royal College of Surgeons of England also awarded up to 10 points for Thursday and Friday. BTOG 2015 attracted 723 attendees. BTOG 2015 included 8 sponsored satellite meetings on Wednesday, Thursday and Friday and BTOG also held specialist symposia on Wednesday on the subjects of Translational Research, Respiratory Medicine and Radiotherapy Training BTOG Attendees Year Feedback from BTOG 2015 Very good, well organised conference. Excellent discussion on topical areas surrounding thoracic medicine and surgery - particularly focus on ongoing research helpful and inspiring. Sessions ran to time and discussion encouraged. Wonderful conference. I thoroughly enjoyed all of the sessions, with a fantastic mix of topics ranging from basic science to surgery. The question and answer part of the talks were also very informative and useful. Superb mix of speakers and topics. The conference was excellent for networking and enhancing your clinical skills and knowledge. I attend BTOG most years and always learn a lot from an enjoyable meeting. I think the standard of talks was better than ever this year and the structure of the whole event had clearly been thought through carefully. Page 2 of 6

3 BTOG Thoracic Oncology Course th and 13 th May 2014 Leicester The course is aimed at trainees and those entering the thoracic oncology speciality and all members of the MDT. The course was awarded 9 CPD credits from the Royal College of Phycians. Attendance totalled 75. Feedback from BTOG Course 2014 Very informative 2 days, very well organised. Group sessions allow time for interaction/ questions. Really good/refreshing to go to a course which concentrates on practical, relevant day to day practice rather than aspirational future potential treatments. I am new to oncology and found the course very informative and useful. Very informative course, well organised, focussed on daily clinical practice. I really enjoyed the course, it was very relevant to my practice. The presenters were very receptive to questions. Managing Mesothelioma in the UK Meeting in collaboration with Mesothelioma UK 12 th September 2014 London The study day was awarded 5 CPD credits from the Royal College of Physicians. Attendance totalled 119. Feedback from Mesothelioma Meeting Excellent, interactive meeting. Well organised and structured, hotel location easy to find, quality of catering very high. Excellent, well done. Relevant and useful. Liked the trials roundup. Impressive speaker line-up. Good range of speakers. Thank you for the hard work put in to organising. The speakers were all fantastic and definitely gave us all something to think about. Very informative and an eye opener into research into mesothelioma. Very optimistic about the long term development in mesothelioma. Publications Supplement to Lung Cancer journal published by Elsevier BTOG 2015 posters Reference: Lung Cancer 87 Suppl. 1 (2015) ISSN Page 3 of 6

4 A Practical Guide to Lung Cancer Nutritional Care published in January The BTOG steering committee was given the opportunity to comment on the draft guide and the final guide was endorsed by BTOG. BTS Guideline for the investigation and management of Pulmonary Nodules The BTOG steering committee was given the opportunity to comment on the draft guideline (to be published). Collaboration British Thoracic Society BTOG 2015 was held in collaboration with the British Thoracic Society, the European Thoracic Oncology Platform (ETOP), International Association for the Study of Lung Cancer (IASLC), Mesothelioma UK and National Lung Cancer Forum for Nurses (NLCFN). Collaborative sessions BTOG 2015 included the BTOG/British Thoracic Society (BTS)/ NCRI session, the BTOG/SCTS session and BTOG/NCRI subgroups workshops and BTOG/NLCFN workshop. Page 4 of 6

5 Representation BTOG has gained recognition as an appropriate body to review NICE submissions for new drug therapies for thoracic malignancies. Commentator: Pemetrexed for maintenance treatment following induction therapy with pemetrexed and cisplatin for non-squamous non-small-cell lung cancer [ID489] Crizotinib for the treatment of previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene [ID499] Afatinib for treating epidermal growth factor receptor mutation positive locally advanced or metastatic non-small cell lung cancer [ID556] Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed following prior chemotherapy (Review of TA162 and TA175) [ID620] Lung cancer (non-small cell, anaplastic lymphoma kinase positive, metastatic) - LDK378 (post chemotherapy) ID729 BTOG sent a written complaint to the Chair of the Cancer Drugs Fund (CDF) in February 2015 in relation to the decision to withdraw access to pemetrexed through the CDF. BTOG considered that withdrawal of maintenance pemetrexed from the CDF would be a backward step for NSCLC patients in England and would have a direct and negative impact on survival and outcomes. National Lung Cancer Audit Executive The BTOG steering committee is represented on this group by Dr Clive Mulatero (BTOG was invited to join the Executive January 2015). European Thoracic Oncology Platform (ETOP) BTOG is a member group of ETOP and BTOG President Ken O Byrne and BTOG steering committee member Keith Kerr are both members of the ETOP foundation council. The interest in promoting and improving collaboration in clinical and translational research in lung cancer and mesothelioma in Europe prompted investigators representing collaborative study groups and institutions concerned with thoracic malignancies to explore new ways of working together. Out of this discussion the European Thoracic Oncology Platform was founded in International Mesothelioma Interest Group 2016 Local Organising Committee BTOG is represented on this committee by Dr Sanjay Popat. Page 5 of 6

6 Steering Committee The steering committee met 4 times during this year April 2014, June 2014, October 2014 and January Please refer to Appendix A for list of steering committee members during this year. Website: BTOG Membership During this year membership was free of charge and there were >2,000 members. BTOG 2015 registrants (excluding industry) were given honorary membership of BTOG for 1 year from 1 January 2015 to 31 December The benefits of BTOG membership include:- access to the BTOG website ( member area including the document library (including presentations from the annual conference and study days subject to speaker permissions) notification of BTOG annual conference and study days chance to attend BTOG study days that, subject to sponsorship, are offered free of charge for health care professionals involved in thoracic oncology and travel bursaries are also available for travel within the UK and Ireland notification of thoracic oncology conferences/study days/other events circulation of thoracic oncology research and other news related to lung cancer and mesothelioma participation in research (questionnaires, surveys) The British Thoracic Oncology Group Charity (BTOG Charity) During this year Dawn Mckinley, BTOG Operational Manager and steering committee members, John Edwards and Mick Peake have continued to work relating to the setting up of the BTOG Charity. This will be completed during Page 6 of 6